The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Idiopathic Intracranial Hypertension (IIH-Pseudotumor Cerebri) — Ocular Involvement

Elevated cerebrospinal fluid pressure in young obese women causing bilateral papilledema, transient visual obscurations, peripheral visual field constriction, and risk of permanent vision loss; diagnosed by MRI/MRV with empty sella and transverse sinus stenosis, lumbar puncture opening pressure >25 cm H2O, and Modified Dandy criteria; treated with weight loss, acetazolamide, topiramate, optic nerve sheath fenestration, or CSF diversion shunt for fulminant disease.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göz Hastalıkları department. Book Appointment →

What is Idiopathic Intracranial Hypertension (IIH-Pseudotumor Cerebri) — Ocular Involvement?

Idiopathic intracranial hypertension (IIH), historically called pseudotumor cerebri (PTC) or benign intracranial hypertension (the term 'benign' is misleading given vision loss risk), is characterized by elevated intracranial pressure (ICP >25 cm H2O on lumbar puncture, normal CSF composition) without identifiable structural cause. It predominantly affects young obese women: 95 percent female, mean age 28 years, BMI >30. Annual incidence in obese reproductive-age women reaches 19 per 100,000.

Pathophysiology remains incompletely understood but involves impaired CSF outflow at arachnoid villi, transverse sinus stenosis (cause vs. consequence debated), elevated central venous pressure, retinoic acid metabolism disturbance, sex hormone influence, and obesity-related elevated intra-abdominal pressure transmitted to dural venous system. Modified Dandy criteria for diagnosis: (1) signs and symptoms of generalized intracranial hypertension or papilledema, (2) no localizing neurologic findings except CN VI palsy, (3) elevated CSF opening pressure with normal composition, (4) normal neuroimaging excluding hydrocephalus, mass, vascular cause.

Ocular manifestations: bilateral papilledema (Frisén grading 0–5: 0 normal, 1 minimal nasal blurring, 2 obscures vessels at disc margin, 3 obscures major vessel as it leaves disc, 4 partial obscuration of major vessel on disc, 5 obscuration of all vessels), transient visual obscurations (TVOs — momentary unilateral or bilateral graying lasting seconds, especially with bending or Valsalva), gradually progressive visual field constriction (enlarged blind spot earliest, then nasal step, peripheral constriction; central visual acuity preserved until late), photopsias, diplopia from CN VI palsy (false-localizing sign of high ICP), pulsatile tinnitus.

Visual loss occurs in 10 percent of all cases (more in fulminant variant); 1–2 percent develop legal blindness. Risk factors for visual loss: male sex, fulminant onset, severe papilledema (Frisén ≥3), peripapillary hemorrhage, anemia, severe systemic hypertension. Imaging: MRI with MRV shows distended perioptic CSF, posterior globe flattening, optic disc protrusion (papilledema), partially empty sella turcica (70 percent), transverse sinus stenosis (60 percent — often bilateral), normal ventricles. OCT of retinal nerve fiber layer (RNFL) and Bruch membrane opening (BMO) tracks papilledema severity and resolution.

Symptoms

Holocranial pulsatile or tension-type headache worse on awakening or bending
Transient visual obscurations (brief unilateral or bilateral graying lasting seconds)
Pulsatile tinnitus (whooshing in time with heartbeat)
Horizontal diplopia (cranial nerve VI palsy from elevated ICP)
Peripheral visual field loss noticed as 'walking into things' or constriction
Photopsias (flashes of light)
Neck or back pain (CSF distension along nerve roots)
Decreased visual acuity (late finding indicating advanced disease)
Bilateral papilledema with disc edema, hemorrhages, exudates on fundoscopy
Recent weight gain or peripartum onset

Risk Factors

Female sex (95 percent), reproductive age (peak 20–40 years)
Obesity (BMI >30; >40 carries higher fulminant risk)
Recent weight gain (>5–15 percent body weight in past year)
Polycystic ovary syndrome
Pregnancy or peripartum period
Medications: tetracyclines (doxycycline, minocycline), retinoids (isotretinoin), vitamin A toxicity, growth hormone, lithium, withdrawal of corticosteroids
Endocrine: Addison disease, Cushing syndrome, hypoparathyroidism, hyperthyroidism
Renal disease, anemia, sleep apnea
Transverse venous sinus stenosis or thrombosis
Family history of IIH (rare)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe persistent headache with new visual symptoms — emergent
  • Transient blackouts of vision (TVOs) — urgent ophthalmology and neuro-imaging
  • Pulsatile tinnitus with headache and obesity
  • New diplopia in young obese woman
  • Visual field loss or central visual loss — emergent
  • Severe papilledema (Frisén ≥3) on examination
  • Failed conservative therapy with worsening field defects
  • Pregnancy with new severe headache or papilledema
  • Use of tetracycline or retinoid with visual symptoms

Treatment Methods

01
Diagnostic workup per Modified Dandy criteria: complete neuro-ophthalmologic evaluation including dilated fundus examination with disc photography or OCT, automated perimetry (Humphrey 24-2 or 30-2), color vision testing, visual evoked potentials if needed, MRI brain with MRV (with and without contrast — assess transverse sinus stenosis, empty sella, optic nerve sheath distension, posterior globe flattening, exclude mass-thrombosis), lumbar puncture in lateral decubitus for opening pressure >25 cm H2O (no sedation; deep breaths increase pressure falsely) with CSF analysis (cell count, protein, glucose, oligoclonal bands)
02
Lifestyle: weight loss target 5–10 percent body weight (most effective long-term intervention; weight regain is the leading cause of recurrence), salt and caffeine restriction, screening for sleep apnea and treatment if present, discontinue offending medications (tetracyclines, retinoids, vitamin A, hormonal contraceptives if related)
03
First-line medical therapy: acetazolamide (Diamox) 250 mg twice daily titrated upward to 1–4 g daily based on symptoms and tolerability, or sustained release 500 mg twice daily; monitor electrolytes (paresthesias, metabolic acidosis, kidney stones risk), supplement potassium if needed, avoid in sulfa allergy or pregnancy first trimester
04
Adjunctive or alternative: topiramate 25 mg titrated to 100–200 mg/day (provides additional weight loss and headache benefit but cognitive side effects), furosemide 20–80 mg/day (adjunct in refractory disease), methazolamide as acetazolamide alternative
05
Therapeutic lumbar puncture for diagnostic and brief symptomatic relief; not effective long-term; serial LPs not recommended due to risk of intracranial hypotension headache
06
Surveillance: repeat visual fields and OCT every 1–4 weeks initially based on severity, monthly when stable, every 3–6 months long-term; serial fundus photography for papilledema grading
07
Surgical indication for visual deterioration despite maximal medical therapy or fulminant onset: optic nerve sheath fenestration (ONSF — preferred for vision loss with controlled headache), ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt (preferred for refractory headache; LP simpler but higher revision rate, VP more durable), transverse venous sinus stenting (emerging — for stenosis with persistent gradient >8 mmHg)
08
Bariatric surgery (sleeve gastrectomy, Roux-en-Y) for BMI >35–40 with IIH — produces durable remission in many cases when medical therapy alone fails for weight maintenance
09
Pregnancy management: stable or mild IIH can usually be carried; weight gain monitoring; acetazolamide is category C (avoid first trimester); ophthalmology surveillance every trimester; intervention if visual loss; vaginal delivery generally safe
10
Long-term: recurrence rate 10 percent (especially with weight regain); annual ophthalmologic follow-up indefinite; multidisciplinary team (neurology, ophthalmology, neurosurgery, dietitian, sleep medicine) for fulminant or refractory cases

Which Department to Visit?

You can visit our Göz Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göz Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.